These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 19505269)
41. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. Willette RN; Eybye ME; Olzinski AR; Behm DJ; Aiyar N; Maniscalco K; Bentley RG; Coatney RW; Zhao S; Westfall TD; Doe CP J Pharmacol Exp Ther; 2009 Sep; 330(3):964-70. PubMed ID: 19556450 [TBL] [Abstract][Full Text] [Related]
42. The role of serotonin in cardiovascular disease. Frohlich ED J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S1-2. PubMed ID: 2446053 [No Abstract] [Full Text] [Related]
43. [Physiopathology and prognosis of hypertension]. Omae T Nihon Naika Gakkai Zasshi; 1984 Feb; 73(2):183-5. PubMed ID: 6726046 [No Abstract] [Full Text] [Related]
44. Behavior and cardiovascular function. Herd JA Physiologist; 1971 May; 14(2):83-9. PubMed ID: 5088085 [No Abstract] [Full Text] [Related]
45. Micronutrient prenatal supplementation prevents the development of hypertension and vascular endothelial damage induced by intrauterine malnutrition. Franco Mdo C; Ponzio BF; Gomes GN; Gil FZ; Tostes R; Carvalho MH; Fortes ZB Life Sci; 2009 Aug; 85(7-8):327-33. PubMed ID: 19576906 [TBL] [Abstract][Full Text] [Related]
46. Risk factors: Mechanistic insights into the cardiovascular benefits of a Mediterranean diet. Lim GB Nat Rev Cardiol; 2014 Aug; 11(8):433. PubMed ID: 24981142 [No Abstract] [Full Text] [Related]
51. Blocking the renin-angiotensin system: dual- versus mono-therapy. Ravandi A; Teo KK Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282 [TBL] [Abstract][Full Text] [Related]
52. Essential hypertension: is there a role for inflammatory mechanisms? Androulakis ES; Tousoulis D; Papageorgiou N; Tsioufis C; Kallikazaros I; Stefanadis C Cardiol Rev; 2009; 17(5):216-21. PubMed ID: 19690472 [TBL] [Abstract][Full Text] [Related]
53. [Role of gas signaling molecule hydrogen sulfide in cardiovascular diseases]. Wang XB; Jin HF; Du JB Zhongguo Dang Dai Er Ke Za Zhi; 2009 Sep; 11(9):790-3. PubMed ID: 19755041 [No Abstract] [Full Text] [Related]
54. [Structural-functional properties of the vascular wall in hypertensive patients with coronary heart disease: effects of felodipin and perindopril]. Musikhina NA; Iuferova OV; Gapon LI; Makhneva EA; Belikova EA; Petelina TI; Todosiĭchuk VV Ter Arkh; 2009; 81(9):13-6. PubMed ID: 19827645 [TBL] [Abstract][Full Text] [Related]
55. Central obesity and insulin resistance in the cardiometabolic syndrome: pathways to preclinical cardiovascular structure and function. Klaus JR; Hurwitz BE; Llabre MM; Skyler JS; Goldberg RB; Marks JB; Bilsker MS; Schneiderman N J Cardiometab Syndr; 2009; 4(2):63-71. PubMed ID: 19614791 [TBL] [Abstract][Full Text] [Related]
56. Proceedings of the meeting New Insights and Therapeutic Strategies in Cardiovascular Disease: Focus on Endothelial Targets. Venice, Italy, April 28-29, 2000. J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S1-87. PubMed ID: 12125590 [No Abstract] [Full Text] [Related]
58. Towards understanding the aetiology and pathophysiology of human hypertension: where are we now? Kakar P; Lip GY J Hum Hypertens; 2006 Nov; 20(11):833-6. PubMed ID: 16929340 [No Abstract] [Full Text] [Related]
59. Long-term prognostic value of endothelial dysfunction in patients with chest pain and angiographically normal coronary arteries. Sánchez-Recalde A; Galeote G; Moreno R; Dobarro D; Gómez-Rubín MC; Calvo L; Sobrino N; Martin-Reyes R; Jiménez-Valero S; Sobrino JA; López-Sendón JL Rev Port Cardiol; 2009; 28(7-8):785-91. PubMed ID: 19894657 [TBL] [Abstract][Full Text] [Related]